Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

There are several types of tic disorders with overlapping and distinct symptoms. Keep reading to learn the basics about their causes, triggers, and treatment options.

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

- Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit - ...

NEW YORK, Nov. 14, 2024 /PRNewswire/ -- Fortune announced the inaugural list of the Fortune 100 Most Powerful People in Business, featuring agile disruptors, name-brand titans, Fortune 500 CEOs, and ...

In the runner up spot for lowest paid medical specialty is pediatrics at $259,579. Pediatricians provide care for babies, ...

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis ...

An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...

Then there’s physical activity: Many of the symptoms of lupus, such as joint pain, fatigue, and depression, may make patients ...

As Netflix releases new documentary - The King of Rock and Roll: The Fall and Rise of Elvis Presley, we have taken a look ...

UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...